{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-210399","form_type":"8-K","ticker":null,"cik":"0001851194","company_name":"Ventyx Biosciences, Inc.","filed_at":"2024-08-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.916783+00:00","generated_at":"2026-05-31T06:51:18.155313+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Ventyx CFO Martin D. Auster departs; Roy Gonzales appointed interim CFO/PAO","bullets":["Appointed Roy M. Gonzales as interim principal financial officer and interim principal accounting officer effective Aug 30, 2024, replacing Martin D. Auster.","Dr. Auster's separation agreement provides nine months base salary continuation, COBRA reimbursement, and accelerated vesting of equity vesting within three months.","Gonzales joined as SVP of Finance in April 2024; previously VP of Accounting; salary $350k, 30% target bonus.","No changes to Gonzales' compensation or terms from his interim appointment.","No family relationships or material transactions with Gonzales requiring disclosure."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-210399","json":"https://secwatch.observer/filing/0001193125-24-210399.json","markdown":"https://secwatch.observer/filing/0001193125-24-210399.md","text":"https://secwatch.observer/filing/0001193125-24-210399.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1851194/000119312524210399/0001193125-24-210399-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1851194/000119312524210399/d884852d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T06:51:18.155313+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"80a31d089e","claim":"Roy M. Gonzales was appointed as interim principal financial officer and interim principal accounting officer at Ventyx Biosciences, Inc..","evidence_excerpt":"appointed Roy M. Gonzales, the Company’s Senior Vice President of Finance, as the Company’s interim principal financial officer and interim principal accounting officer, effective as of August 30, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1851194/000119312524210399/0001193125-24-210399-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"interim principal financial officer and interim principal accounting officer"}],"fact_type":"executive_change"},{"claim_id":"f0a2681081","claim":"Martin D. Auster resigned as Chief Financial Officer at Ventyx Biosciences, Inc..","evidence_excerpt":"Dr. Auster ceased employment as the Company’s Chief Financial Officer, effective as of August 30, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1851194/000119312524210399/0001193125-24-210399-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}